<DOC>
	<DOCNO>NCT02445326</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety OTX-DP sustain release drug ( dexamethasone ) depot place canaliculus eyelid treatment sign symptom chronic allergic conjunctivitis .</brief_summary>
	<brief_title>Study Evaluating Efficacy Safety OTX-DP Treatment Chronic Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Be least 18 year age either sex race Have positive history ocular allergy positive skin test reaction perennial allergen Have calculate bestcorrected visual acuity 0.7 logMAR good eye measure use ETDRS chart Have know contraindication sensitivity use investigational product medication component Have history refractive surgery , include LASIK procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>